摘要
目的探究白蛋白结合型紫杉醇新辅助化疗对宫颈癌患者术后疗效的影响。方法选取宫颈癌患者104例,根据治疗方法不同将患者分为治疗组与对照组,每组各52例。对照组患者接受顺铂联合紫杉醇新辅助化疗治疗;治疗组患者接受顺铂联合白蛋白结合型紫杉醇新辅助化疗治疗。结果治疗前,两组患者的瘤体最大直径比较,差异无统计学意义(P﹥0.05);治疗后,治疗组患者的瘤体最大直径明显小于对照组(P﹤0.01)。治疗组患者的术中出血量明显少于对照组(P﹤0.01),单次给药时间、手术时间明显短于对照组(P﹤0.01)。治疗过程中,治疗组患者的荨麻疹及低血压发生率均低于对照组(P﹤0.05);两组患者周围感觉神经病变及肾功能异常发生率比较,差异无统计学意义(P﹥0.05)。治疗组患者化疗总有效率高于对照组(P﹤0.05);治疗组患者的术后1年复发率低于对照组(P﹤0.05)。结论白蛋白结合型紫杉醇相对普通紫杉醇具有不良反应轻,疗效明显,患者耐受性好等优势。
Objective To explore the effect of neoadjuvant chemotherapy containing albumin - bound paclitaxel on postoperative outcomes in patients with cervical cancer. Method 104 cases of patients with cervical cancer who came to our hospital for treatment were divided into treatment group and control group according to their treatment modes, with 52 cases in each team. The patients in control group were given neoadjuvant chemotherapy regimen comprised of cisplat- in plus paclitaxel, and the patients in treatment group were given neoadjuvant chemotherapy regimen comprised of cisplat- in plus albumin-bound paclitaxel. Result Before treatment, there were no statistically significant differences in maxi- mum tumor diameters between two groups （P〉0.05）; After treatment, the maximal tumor diameters of the patients in the treatment group were significantly smaller than those in the control group （P〈0.01）. The intraoperative blood loss of the treatment group was significantly less than that of the control group （P〈0.01）. Single administration time and operation time were significantly shorter than those of the control group （P〈0.01）. The incidences of urticaria and hypotension in the treatment group were both lower than those in the control group （P〈0.05）. There was no significant difference in the incidence of sensory neuropathy or in that of renal dysfunction between the two groups （P〉0.05）. The total effective rate of chemotherapy in the treatment group was higher than that in the control group （P〈0.05）. The recurrence rate during the first year after surgery in the treatment group was lower than that in the control group （P〈0.05）. Conclusion Compared with laaclitaxel, albumin-bound paclitaxel has mild adverse reactions, obvious curative effect and good tolerance.
出处
《癌症进展》
2017年第3期259-261,266,共4页
Oncology Progress
关键词
白蛋白结合型紫杉醇
新辅助化疗
宫颈癌
疗效
albumin-bound paclitaxel
neoadjuvant chemotherapy
cervical cancer
curative effect
